June 2020

BALTIMORE, June 4, 2020 /PRNewswire/ — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG4217, was approved on May 23, 2020. […]

BALTIMORE, June 4, 2020 /PRNewswire/ — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, announced that it concluded on May 18 its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the company’s COVID-19 vaccine candidate, EXG-5003.